DCA Vantage Analyzer
Drive diabetic patient compliance with trusted, clinically proven results

DCA Vantage Analyzer
 
Purchase Options

The DCA Vantage Analyzer is a point-of-care system that helps you monitor glycemic control and detect early kidney disease.

  • CLIA-waived HbA1c test that is IFCC and NGSP-certified
  • 1µl finger stick without fasting – HbA1c results in 6 minutes
  • Random urine sample provides A:C ratio in 7 minutes
  • Requires no sample or reagent preparation prior to testing
  • New 2-D bar-code scanner — for the DCA Vantage® Analyzer and CLINIITEK Status® Connect System

 

DCA Vantage Analyzer

Watch animation
New 2-D barcode scanner.

New 2-D barcode scanner.

DCA Vantage Analyzer

Actionable results in 7 minutes or less

Minimize the need for follow-up visits with a full spectrum of results: HbA1c (NGSP certified and IFCC certified/CLIA waived), Estimated Average Glucose*, Albumin, Creatinine, and Albumin-to-Creatinine Ratio results.
*Not available in the US
DCA Vantage Analyzer

Easy to use in the office or clinic

No sample or reagent preparation is required, and the system provides versatile data management and reporting options
Robust technology delivers proven performance

Robust technology delivers proven performance

The analyzer leverages robust technology and delivers the proven performance of the DCA HbA1c and DCA Microalbumin/Creatinine tests highlighted in more than 140 clinical articles.
Manage diabetes testing in decentralized settings

Manage diabetes testing in decentralized settings

Powerful functionality enables POC coordinators to better manage diabetes testing in decentralized settings. When supported by Siemens RAPIDComm® Data Management System, coordinators can oversee and troubleshoot multiple connected analyzers in real time.

Features & Benefits

Monitor glycemic control and diabetes complications using an analyzer designed to make consultations easier. Fast, actionable test results enable you to determine the effectiveness of a treatment plan, make therapeutic adjustments with confidence, and be more certain whether patients are complying with your recommendations.

Monitor glycemic control

  • HbA1c from a small (1 µL) whole blood sample in 6 minutes
  • Flexible reporting of HbA1c% (NGSP, JDS, and Mono-S units) and IFCC (mmol/mol)
  • HbA1c patient trending graphs can be viewed or printed
     

Detect early kidney disease

  • Albumin, Creatinine, and Albumin-to-Creatinine (A:C) ratio from a urine specimen in 7 minutes to report a quantitative protein status with automatic creatinine adjustment
  • Onboard GFR calculator indexes kidney function 


Improve workflow in the office or clinic

  • Self-contained cartridges facilitate easy, walkaway operation after sample loading
  • No sample or reagent preparation required
  • Bar-code scanner for safer and faster patient/operator ID entry
  • Review results on-screen or generate a hard copy report to minimize transcription errors in the office
  • Convenient local storage of up to 4,000 onboard records with powerful sorting capabilities
  • Automatically upload results to a PC via a USB flash drive to reduce manual logging and save time
  • Minimal maintenance requirements with automatic reminders to alert you when maintenance is due 


Simplify management of diabetes testing in decentralized settings

  • Customizable security access modes support up to 1,000 operators, protect patient information, and prevent operation by unauthorized users
  • POCT1-A2 communication protocol streamlines data transfer for easy connectivity and fast, two-way communication to LIS/HIS, RAPIDComm® System, or other third-party POC data management systems
  • Automatically upload results and QC information to LIS/HIS to reduce manual logging and save time
  • Take testing oversight to the next level with RAPIDComm Data Management System to remotely manage multiple analyzers and operators to enhance compliance and improve risk management. POC coordinators can standardize test procedures, enforce QC protocols, control access privileges, define operator recertification requirements, and more. Customized alerts, reports, and audit trails ensure peace of mind and simplify accreditation and inspections 

Assays

Hemoglobin A1c (HbA1c)
Albumin
Creatinine
Albumin-to-Creatinine (A:C) Ratio Results

Formulas for Calculated Results
% HbA1c = (HbA1c/Total Hemoglobin) x 100

GFR = 186 x (plasma creatinine mg/dL)-1.154 x (patient age years)-0.203 x (0.742 if female patient) x (1.210 if African American patient)
 

Formulas for Dual Reporting From IFCC to % HbA1c
NGSP = (0.09148 x IFCC) + 2.152
JDS = (0.09274 x IFCC) +1.724
Mono-S = (0.09890 x IFCC) + 0.884


Formulas for Dual Reporting From % HbA1c to IFCC mmol/mol

IFCC = (10.93 x NGSP) – 23.50
IFCC = (10.78 x JDS) – 18.59
IFCC = (10.11 x Mono-S) – 8.94

Technical Specifications

 

Overview  
System Description Point-of-care immunoassay analyzer
Quantitative Tests Hemoglobin A1c (whole blood): Range: 2.5% to 14% (4mmol/mol to 130 mmol/mol) Microalbumin/Creatinine (urine): Single test reports all three results for: Albumin: 5 to 300 mg/L; Creatinine: 15 to 500 mg/dL (1.3 to 44.2 mmol/L); Albumin-to Creatinine Ratio: 1 to 2000 mg/g (0.11 to 226 mg/mmol)
Test Format Self-contained immunoassay cartridges
Test Measurement Automatic, optional transmission
Test Method HbA1c: monoclonal antibody agglutination reaction
Albumin: polyclonal goat anti-human albumin antiserum
Creatinine: Benedict Behre chemical reaction
Time to Test Results HbA1c - 6 minutes
  A:C Ratio - 7 minutes

 

 

Test Handling  
Sample Volume HbA1c - 1µL whole blood
Microalbumin/Creatinine - 40µL urine
Sample Preparation No pretreatment; no pipetting required
Sample ID/Operator ID Entry Optional; via touch screen or bar code reader

 

Calibration  
Calibration

Lot-specific calibration card provides automatic calibration with every cartridge

Traceable to International Federation of Clinical Chemistry (IFCC) reference materials and test methods for measurement of HbA1c

 

Onboard Computer  
Storage Capacity/Memory 4000 patient and/or control records
Up to 1,000 operator IDs
Display Color touch screen with 1/4 VGA resolution
Data Export Via USB flash drive to PC or direct to LIS/HIS or data manager, if interfaced

 

Quality Control/Compliance  
Flexible QC Scheduling None, Automatic Reminders or Required
QC Testing Optional lockout if schedule not followed or QC fails
User/Operator Access Restricted, if desired, to protect patient and QC data and prevent unauthorized use
Matching Lab Results/
Reference Method

Adjustable correlation to reference methods
Reference Ranges User-definable reference ranges available for HbA1c

 

Computer/Peripheral Interfaces  
Serial Port RS232, ASTM
Ethernet Connection ASTM or POCT1-A2
Bi-Directional Capabilities ASTM: Remote computer can be set up to lock out patient tests
POCT1-A2: Remote computer can be set up to lock out patient tests, and send operator list to analyzer
USB-Port Standard USB 2.0
External Bar Code Reader (optional) Serial (9 pin)
Onboard Printer 54 mm (2 in) width, thermal/label stock
External Printer Supports standard PCL printer interface via USB port

 

General  
Dimensions

9.0 (h) x 11.5 (w) x 10.5 (d) inches 25.4 (h) x 28.7 (w) x 27.7 (d) cm

Weight

3.88 kg (9.0 lb)

Power Requirements

100 to 240 VAC; 50/60 Hz

Line Leakage Current

<0.3 mA in normal condition
<0.5 mA in single fault condition

Maximum Power Input

70 VA; 30 watts

Ambient Operating Temperature

18°C to 30°C (64°F to 86°F) (Albumin)
15°C to 32°C (61°F to 88°F) (HbA1c)

Operating Temperature

5°C to 40°C (41°F to 104°F);
15% to 90% relative humidity

Safety

TUV SUD with CB Scheme, CSA-C22.2,
EN60601, IEC 60601, UL60601

EMC Emissions/Immunity

FCC 47: Part 15 (Class B),
EN60601-1-2 (Class B)

 


Share this page:

Related Products, Services & Resources

References
1. Lenters-Westra E, Slingerland RJ. Clin Chem 2010;56(1):44.
2. Thaler LM, et al. Diabetes Care 1999;22:1415-21.
3. Miller CD, et al. Diabetes Care 2003;26:1158-63.
4. Cagliero E, et al. Diabetes Care 1999;22:1785-9.
5. GHX Market Intelligence, market data report. 4Q 2012 Report.